Figure 2. Only the highest dose of the receptor for advanced glycation endproducts (RAGE) inhibitor significantly inhibited the diabetes-induced increase in retinal intercellular adhesion molecule-1 (ICAM-1) expression. Diabetics were treated with 0, 10, 100, or 300 μg/day of the RAGE-Immunoglobulin fusion protein. Only the highest dose of inhibitor significantly inhibited retinal ICAM-1 expression below that seen in control diabetics. The duration of diabetes and drug administration was 2 months. n=6–10 in all groups.